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Ovarian Toxicity and Carcinogenicity in
Eight Recent National Toxicology Program
Studies
by Robert R. Maronpot*
Ovarian toxicity and/or carcinogenicity has been documented for at least eight chemicals recentlytested
inNational ToxicityProgram prechronic andchronicrodentstudies. Thechemicalsthatyieldedtreatment-
related ovarian lesions were 1,3-butadiene, 4-vinylcyclohexene, vinylcyclohexene deipoxide, nitrofuran-
toin, nitrofurazone, benzene, A-9-tetrahydrocannabinol, and tricresylphosphate. Typical nonneoplastic
ovarian changes included hypoplasia, atrophy, follicular necrosis, and tubular hyperplasia. The most
commonly observed treatment-related neoplasms were granulosa cell tumors and benign mixed tumors.
A relationship between antecedent ovarian hypoplasia, atrophy, and hyperplasia and subsequent ovarian
neoplasia is supported by some ofthese National Toxicology Program studies. Pathologic changes in other
tissues such as the adrenal glands and uterus were associated with the treatment-related ovarian changes.
Ovarian and Reproductivity Toxicity
Normal ovarian functional and morphologic integrity
is inextricably associated with properfunctioning ofthe
HPOU (hypothalamus-pituitary-ovary-uterus) system
(1-3). Consequently, reproductive perturbations can re-
sult from functional and/or morphologic compromise of
any part of this system. The frequency of treatment-
related ovarian lesions in general toxicity testing ap-
pears to be low. Thus, characterization and understand-
ing of ovarian lesions when they do occur pose difficul-
ties because ofthe lack of substantial knowledge about
the ovary as a target tissue for toxicity. Even in rodent
reproductive toxicity studies, significant ovarian pa-
thology is usually not found. This is largely a conse-
quence ofthe greater emphasis given to functional per-
turbations in reproductive performance in these
studies. Specific ovarian lesions such as oocyte necrosis
and premature atresia have been produced by exposure
to ionizing radiation (4) or to chemicals such as some
polycycic aromatic hydrocarbons, alkyl halides, and ni-
trosamines (4-6). Follicular cysts and reduction in num-
ber of corpora lutea have been associated with estro-
genic action of DDT and its analogs (7).
In the human clinical setting, occupational exposure
of women to chemicals is not frequently associated with
specific ovarian lesions. In a review of 270 reports re-
lating to clinical manifestations of female reproductive
toxicity (8), approximately 45% ofthe reports deal with
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toxicity to the embryo, fetus, or placenta. Another40%
discuss perturbations of the integrated functioning of
the HPOU axis. Ovarian toxicity per se represents a
small proportion of the alterations, and these usually
involve hormonal dysfunctions. An expanded discussion
of the association between ovarian toxicity and occu-
pational exposure to chemicals is contained in a recent
review (3). Similarly, specific functional or morphologic
effects on the ovary represent a small proportion of
untoward effects of chemicals on the rodent reproduc-
tive system as judged by the low frequency of occur-
rence ofovarianlesionsinstandardtoxicitystudies such
as those conducted bythe National Toxicology Program
(NTP) or in noninvasive reproductive toxicity studies
(9). Functional deficitsinreproductive performance and
altered development ofreproductive capacityinrodents
have been associated with awide spectrum ofchemicals
(10,11). Ovarian lesions have not been specifically doc-
umented in these latter studies.
Chemicals that are toxic to the female reproductive
system act either directly or indirectly (12). Direct-act-
ing toxins are often structurally similar to biologically
important molecules or are chemically reactive com-
pounds that behave nonspecifically. Examples of the
former include nutrients or hormones that act as ago-
nists orantagonists ofendogenous hormones. Examples
ofchemically reactive nonspecific compounds include al-
kylating agents, denaturants, and chelators. Indirect-
acting toxins exert their toxicity either by being met-
abolically activated to active toxins (e.g., cyclophos-
phamide, dibromochloropropane, polycyclic aromatic
hydrocarbons) or by induction or inhibition of repro-
ductively important enzyme systems. Since the ovaryR. R. MARONPOT
contains microsomal monooxygenases, epoxide hy-
drases, and transferases (5,12), the ovary may meta-
bolically activate chemicals with consequent production
of ovarian lesions.
Ovarian Neoplasia
Based upon epidemiological studies in nulliparous
women, it appears that endogenous hormones are as-
sociated with the induction orgrowth ofovarian tumors
(13-15). Further, it has been postulated that gonadal
failure may be a common perturbation for both infer-
tility and ovarian neoplasia (16). Based upon the known
presenceofspecifichormone receptorsinovariantissue,
it is reasonable to anticipate that endogenous hormones
(e.g., gonadotropins, estrogens, progesterones, andro-
gens, corticosteroids) would influence the clinical be-
havior of benign and malignant ovarian neoplasms in
humans and animals.
From results of experimental studies, a sequence of
events has been postulated relative to the development
of granulosa cell tumors and tubular adenomas in ro-
dents (17-21). These investigators hypothesize that de-
generation of follicular granulosa cells subsequent to
oocyte destruction stimulates a compensatory increase
inpituitarygonadotropinswhich, inturn, stimulatescell
proliferation and eventual development of neoplasia.
While such a mechanism may be associated with de-
velopment ofovarianneoplasiainmaturerodents, ovar-
ian tumors in pubertal rodents can develop in the pres-
ence of a normal population of growing oocytes and
follicles (22). A similar mechanism associated with in-
terruption ofthe normal hormonal feedback system be-
tween ovary and hypothalamus/pituitary is seen in ex-
periments where normal ovarian tissue is grafted to the
spleen of ovariectomized rodents (23). Since venous
drainage from the spleen passes through the liver, hor-
mones produced by the grafted ovary are metabolized,
and thus, the feedback necessary to prevent release of
pituitary gonadotropins is interrupted. The result is
continued production of pituitary gonadotropin, which
stimulates celi proliferation in the grafted ovary and
leads to development ofgranulosa cell tumors.
Hormonally mediated induction of ovarian tumors in
rodents has also been demonstrated following neonatal
thymectomy (24), as well as following parabiosis with a
castrate, transplantation ofagonadotropic pituitary tu-
mor, or chronic exposure to hormones (23).
Ovarian Toxicity and
Carcinogenicity in NTP Studies
Ovarian toxicity and/or carcinogenicity has been ob-
served for aleast eightchemicals inrecent NTPtoxicity
and/orcarcinogenicity studies. Three ofthese chemicals
are closely related structurally: 1,3-butadiene, 4-vinyl-
cyclohexene, and vinylcyclohexene diepoxide.
1,3- Butadiene
1,3-Butadiene is a four-carbon aliphatic used as an
intermediate in production ofelastomers and polymers.
Its largest use is in synthetic rubber production, and in
that setting, it is primarily an air contaminant. Occu-
pational exposure is estimated at 62,000 workers an-
nually.
1,3-Butadiene also occurs in urban atmospheres as a
combustion product of fossil fuels. 1,3-Butadiene is
clearly carcinogenic, as shown by a recently completed
inhalationstudyinB6C3F1 mice (25,26). Thisstudywas
prematurely terminated because ofhigh mortality sec-
ondary to neoplasia after 61 weeks of inhalation expo-
sure to 625 or 1250 ppm 1,3-butadiene. In addition to
causing ovarian tumors, 1,3-butadiene caused heman-
giosarcomas of the heart, malignant lymphomas, lung
tumors, and forestomach tumors in male and female
mice and mammary gland tumors and liver tumors in
female mice (25).
Ovarian lesions in mice exposed to 1,3-butadiene for
up to 60 weeks included loss offollicles, tubular hyper-
plasia, and several different tumor types (Tables 1 and
2). One of the granulosa cell tumors in the 1250 ppm
group was malignant. Neoplasms with both a tubular
cell component and a granular cell component were di-
agnosed as "benign mixed tumor." Epithelial hyperpla-
sia refers to a proliferation oftubular structures in the
ovarian parenchyma and is regarded as a precursor to
tubular adenoma in the context of this specific 1,3-bu-
tadiene study. Significant microscopic lesions were not
present in the ovaries following either 15 days or 14
weeks of inhalation exposure to 625, 1250, 2500, 5000,
or 8000 ppm 1,3-butadiene.
4-Vinylcyclohexene
4-Vinylcyclohexene is a dimer of 1,3-butadiene. It is
a high-volume chemical used in the production ofepoxy
Table 1. Findings of 1,3-butadiene study.
Ovarian Other pathologic
pathologic findings in
Study Species findings females
90-day Mouse None None
inhalation
61-week Mouse Atrophy Liver neoplasia
inhalation Hyperplasia Heart neoplasia
Neoplasia Lymphoma
Lung neoplasia
Forestomach neoplasia
Mammary neoplasia
Table 2. Numbers of mice with neoplastic and nonneoplastic
ovarian lesions in the 61-week inhalation study of 1,3-butadiene.
Exposure group
Control 625 ppm 1250 ppm
No. ofmice examined 49 45 48
Lesion
Granulosa cell tumor 0 6 13
Tubular adenoma 0 2 0
Benign mixed tumor 0 0 2
Cystadenoma 0 1 0
Granulosa cell hyperplasia 0 2 0
Epithelial hyperplasia 0 3 0
Atrophy 2 40 40
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resins and is present in gases discharged during the
curingofsynthetic rubber. It was administered by gav-
age to rats and mice in a 90-day toxicity study and a 2-
year carcinogenicity study (doses: 200 and 400 mg/kg
body weight) (27). While there were no significant mi-
croscopic lesions in females in the 90-day rat study,
ovarian atrophy (reduction in the number of primary
and mature graafian follicles) and mild gastritis were
documented in treated mice. Following 2 years of ex-
posure, 4-vinylcyclohexene produced ovarian hyperpla-
sia and neoplasia in mice (Tables 3 and 4) but not in
rats. In addition, there was treatment-related cytologic
degeneration in the adrenal cortex, as well as adrenal
cortical neoplasia, in female mice. 4-Vinylcyclohexene
produced clitoral gland neoplasia in female rats but was
concluded to be an inadequate study in female rats be-
cause ofextensive early mortality in both dose groups.
Vinylcyclohexene Diepoxide
Vinylcyclohexene diepoxide is a potential metabolic
product of 4-vinylcyclohexene. Its primary use is as a
reactivediluentforepoxyresins. Occupationalexposure
is chiefly by the dermal route. Vinylcyclohexene di-
epoxide hasbeentestedbygavageand dermalexposure
routes for 90 days in rats and mice and is currently
being tested in a 2-year dermal study in rats and mice.
While treatment-related ovarian lesions were not ob-
served in either 90-day rat study, treatment-induced
ovarian atrophy was found in the 90-day mouse dermal
study (Table 5). At the 65-week interim sacrifice ofthe
Table 3. Findings of4-vinylcyclohexene study.
Ovarian Other pathologic
pathologic findings in
Study Species findings females
90-day gavage Rat None None
90-day gavage Mouse Atrophy Gastritis (minimal)
2-year gavage Rat None Clitoral gland
neoplasia
2-year gavage Mouse Hyperplasia Adrenal cortical
Neoplasia degeneration
Adrenal cortical
neoplasia
Table 4. Numbers of female mice with selected ovarian lesions
in the 2-year gavage study of4-vinylcyclohexene.a
Exposure group
Control 200 mg/kg 400 mg/kg
No. of mice examined 49 48 47
Lesions
Benign mixed tumor 0 25 11
Tubular adenoma 0 2 1
Tubular hyperplasia 1 10 13
Granulosa cell tumor 1 9 11
Granulosa cell carcinoma 0 1 2
Granulosa cell hyperplasia 0 5 1
'A few other neoplastic and hyperplastic lesions were present in a
small number of mice (27).
Table 5. Findings ofvinylcyclohexene diepoxide study.
Ovarian Other pathologic
pathologic findings in
Study Species findings females
90-day gavage Rat None Forestomach
hyperplasia, toxic
nephrosis,
pancreatic
atrophy, uterine
atrophy,
90-day gavage Mouse None Forestomach
hyperplasia,
uterine atrophy
90-day dermal Rat None Skin irritation
90-day dermal Mouse Atrophy Skin irritation,
uterine atrophy
2-year dermal Rat at 65 weeks: None Skin irritation
2-year dermal Mouse at 65 weeks: Skin irritation
Atrophy,
hyperplasia,
neoplasia
Table 6. Findings of nitrofurantoin study.
Ovarian Other pathologic
pathologic findings in
Study Species findings females
90-day feed Rat Follicular epithelial None
cell necrosis
90-day feed Mouse Follicular epithelial None
cell necrosis
2-year feed Rat None None
2-year feed Mouse Atrophy, Adrenal hyperplasia,
hyperplasia, liver neoplasia
neoplasia
Table 7. Findings of nitrofurazone study.a
Ovarian Other pathologic
pathologic findings in
Study Species findings females
90-day feed Rat Pale, Uterine
vacuolated hypoplasia,
interstitial bone lesions,
cells muscle lesions
90-day feed Mouse None Thymic atrophy
2-year feed Mouse Hyperplasia, None
neoplasia
aData for 2-year feed study in rats not yet available.
2-year dermal study, ovarian atrophy, tubular hyper-
plasia, and neoplasia were present in mice. No ovarian
lesions were found inrats atthe interim sacrifice. While
finalconclusionsregardingovariancarcinogenicitymust
await completion of the 2-year study, based upon 65-
week data, it is probable that vinylcyclohexene diepox-
ide will be considered an ovarian carcinogen in B6C3F1
mice.
Studies in progress on two related chemicals, nitro-
furantoin and nitrofurazone, have shown a neoplastic
response in the ovary (Tables 6 and 7). Nitrofurantoin
is a commonly used urinary antibiotic. Nitrofurazone is
a topical antibiotic dressing. The ovarian responses in
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the carcinogenicity studies of these two compounds is
important because ofthe widespread use ofthese chem-
icals and also because the studies represent examples
of carcinogenicity test results wherein the neoplastic
effect is primarily restricted to the ovary. Although the
results oftoxicity and carcinogenicity testing should be
regarded as preliminary until all aspects ofthe studies
are peer reviewed, it is apparent at this time that the
ovary was a primary target tissue for both chemicals.
Nitrofurantoin
Nitrofurantoin was administered by dosed feed to
rats and mice. In the 90-day toxicity study, necrosis of
ovarianfollicularepithelialcellswasdocumentedinboth
rats and mice and was the principal pathologic finding
in the 90-day studies. Results (not peerreviewed) from
the 2-year carcinogenicity studies indicate no treat-
ment-associated lesions inthe ovaries ofrats. However,
ovarian atrophy, tubular hyperplasia, and neoplasia
were observed in treated mice (Table 6). In addition,
adrenal hyperplasia and hepatic neoplasia were seen in
treated female mice.
Nitrofurazone
Inthe 90-daynitrofurazone dosed feedtoxicity study,
there was pallor and vacuolization ofthe ovarian inter-
stitial cells in rats, but no ovarian changes were asso-
ciated with treatment in mice. Uterine hypoplasia was
also documented in the 90-day rat study. While data
are not yet available from the 2-year feeding study in
rats, treatment-associated ovarianhyperplasia and neo-
plasiawere observed inthe2-yearcarcinogenicity study
in mice (Table 7).
Pathologic changes in the ovaries have been docu-
mented in studies on at least three additional unrelated
chemicals: benzene, A-9-tetrahydrocannabinol, and tri-
cresylphosphate.
Benzene
In 90-day and 2-year studies, benzene was adminis-
tered by gavage. While there were no pathologic find-
ings in the ovaries of rats or mice in the 90-day study
or in rat ovaries in the 2-year study, ovarian atrophy,
cysts, hyperplasia, andneoplasiawere observed inmice
treated for 2 years (Table 8). The diagnoses and fre-
quencies of the ovarian tumors in mice are detailed in
Table 9. It should be noted thatbenzenewasconsidered
carcinogenic in both rats and mice, producing a wide
spectrum of epithelial tumors in several tissues (28).
The observation ofsignificant ovarian neoplasia in mice
was an unexpected finding at final sacrifice.
A-9-tetrahydrocannabinol
At the present time, A-9-tetrahydrocannabinol has
beentestedbygavageadministration for90daysinrats
and mice. Two-year studies in both species are planned.
Table 8. Findings of benzene study.
Ovarian Other pathologic
pathologic findings in
Study Species findings females
90-day gavage Rat None None
90-day gavage Mouse None None
2-year gavage Rat None Uterine neoplasia,
Zymbal gland
neoplasia, oral
cavity neoplasia
2-year gavage Mouse Atrophy, cysts, Lymphoma,
hyperplasia, mammary
neoplasia neoplasia, lung
neoplasia, Zymbal
gland tumors,
adrenal capsular
hyperplasia,
forestomach
neoplasia,
Harderian gland
neoplasia
Table 9. Numbers of mice with selected ovarian lesions in the 2-
year gavage study of benzene.
Exposure group
Control 25 mg/kg 50 mg/kg 100 mg/kg
No. of mice examined 47 44 49 48
Lesions
Atrophy 15 35 32 22
Epithelial hyperplasia 12 39 31 29
Papillary cystadenoma 0 0 2 1
Granulosa cell tumor 0 1 6 8
Luteoma 0 2 3 2
Tubular adenoma 0 0 3 3
Mixed tumor (benign) 0 1 12 7
Whiletreatment-associated uterine hypoplasiawas doc-
umented in both rats and mice, ovarian changes were
seen only in rats at the end of the 90-day study. The
principal pathologic effect in the rat ovaries was hy-
poplasia characterized by a decrease in the size and
number of maturing ovarian follicles. Diagnostic no-
menclature for the observed ovarian changes in rats is
problematic in that it is not possible to reliably distin-
guish between hypoplasia and atrophy by examination
oftissues only at the conclusion ofa90-day study. Atro-
phy implies that the organ was fully formed and then
lost some of its mature structure. Hypoplasia implies
that the ovary is being well formed but is smaller than
normal (a form of ovarian dysgenesis). There was re-
versibility of ovarian lesions within 60 days after the
conclusion ofthe 90-day dosing period.
Tricresylphosphate
Tricresylphosphate has been tested for 90 days by
gavage as well as dosed feed administration inboth rats
and mice. While results have not been peer reviewed
and, thus, shouldberegarded as preliminary, therewas
a treatment-associated hypertrophy and cytoplasmic
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vacuolization of interstitial cells in the ovaries of both
species. In addition, cytologic alterations were noted in
the adrenals of treated female rats and mice. Tricre-
sylphosphate will ultimately be tested for carcinogen-
icity in 2-year studies.
Conclusions
Based uponreviewofthe completed and uncompleted
toxicity and carcinogenicity studies for the eight chem-
icals described, some general conclusions and consid-
erations regarding pathologic evaluation ofovarian tis-
sues seemjustified. First, the occurrence oftreatment-
associated ovarian lesions in 90-day and 2-year rodent
studiesisnotcommon. Todate, morethan300chemicals
have beentestedin90-dayand/or2-yearcarcinogenicity
studies. Significant treatment-related ovarian effects
were found in only eight ofthese studies. This probably
represents an underestimate of the true incidence of
treatment-associated ovarian pathologic changes, since
in past years, 90-day studies were used primarily to set
doses for 2-year studies rather than to define subtle
toxicity. Consequently, in the absence ofgrossly visible
changes, one would not expect ovarian tissues to have
been examined as critically in the past as is currently
done. Despite the possibility that there may be more
thaneight studies inwhich ovarian lesionswereinduced
by treatment, it is still reasonable to conclude that the
frequency of ovarian target tissue toxicity is not high
inconventional rodenttoxicityandcarcinogenicitystud-
ies.
Ovarian function and dysfunction are intimately
linked withthehypothalamus, thepituitary, theuterus,
and other endocrine organs. Thus, the observation that
treatment-associated ovarian changes were frequently
associated with pathologic alterations in other tissues
(e.g., adrenal, uterus)intheeightNTPchemicalstudies
is not surprising. In fact, the low probability that ovar-
ian lesions would occur in isolation should prompt the
pathologist to closely examine all parts of the HPOU
and endocrine systems whenever a lesion is found in
one component of this system. Closer examination of
these other tissues may reveal subtle but important
changes not noted on the initial pathologic examination.
The ovarian lesions documented in the NTP studies
covered by this paper provide supportive evidence that
alterations noted in ovaries of treated rodents at the
conclusion of a 90-day study may herald the ultimate
development ofovarian neoplasia upon continued treat-
ment. A relationship between antecedent ovarian hy-
poplasia, atrophy, and hyperplasia and subsequent
ovarianneoplasiahasbeenpreviouslyproposed (17-21).
Consequently, when ovarian changes are observed in
treated animals in prechronic toxicity studies, special
studydesign considerations (e.g., addingextrafemales,
interim sacrifices, vaginal cytology, hormone measure-
ments) might be warranted in subsequent carcinogen-
icity/chronic toxicity studies. Definitive reproductive
studies would also be warranted when ovarian lesions
occur in a 90-day study.
Histopathologic distinction between ovarian atrophy
and hypoplasia in rodents cannot be reliably made on
the basis ofexamination oftissues onlyatthe conclusion
of a 90-day study. Atrophy implies that the organ was
fully formed and then lost some ofits mature structure.
Hypoplasia implies that the ovary is being well formed
but is smaller than normal (a form of ovarian dysge-
nesis). At the end ofa typical 90-day study, the rats or
mice are approximately 20 weeks of age, and ovarian
tissues would be expected to be fully developed and
functional. The observation ofatrophy or hypoplasia at
this point is problematic inthatthe pathologist does not
know if the ovary became fully developed and then
underwentatrophy oriftheovaryneverfullydeveloped
in the first place and was thus hypoplastic. Since the
distinction between atrophy and hypoplasia maybe me-
chanistically important, it would be appropriate either
to repeat the study and to sample ovarian tissue at
earlier times or to incorporate appropriate interim sac-
rifices early in subsequent chronic toxicity/carcinogen-
icity studies. If ovarian changes are anticipated in ad-
vance, it is recommended that recovery groups be
incorporated into the standard toxicity study.
Histopathologic evaluation ofthe ovary is frequently
frustrated by sampling limitations. Since the ovary is
small, atypical single histologic section may not contain
all tissue elements. Thus, assessment ofthe number of
follicles or corpora lutea may be compromised. Ifovar-
ian changes are anticipated, serial sections from both
ovaries would help ensure adequate amounts of tissue
for examination. By observing similar changes in both
ovaries, the conclusion that the effect is systemic will
besupported. Suchobservations, combined withcareful
examination ofother hormonallyrelated tissues and the
use of interim sacrifices and recovery studies, should
provide appropriate material for a comprehensive his-
topathologic assessment of ovarian toxicity.
The issue of combining tumors for purposes of as-
sessing carcinogenicity is controversial. Ifthe practice
of combining related tumors is followed, it may be in-
appropriate to combine some ovariantumors. The NTP-
recommended nomenclature for rodent ovarian neo-
plasms is based on the cell of origin of the neoplasms.
Tumors arising from diverse cells of origin should not
be combined for purposes ofassessing carcinogenicity.
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